BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Golan T, Kanji ZS, Epelbaum R, Devaud N, Dagan E, Holter S, Aderka D, Paluch-Shimon S, Kaufman B, Gershoni-Baruch R, Hedley D, Moore MJ, Friedman E, Gallinger S. Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers. Br J Cancer 2014;111:1132-8. [PMID: 25072261 DOI: 10.1038/bjc.2014.418] [Cited by in Crossref: 202] [Cited by in F6Publishing: 173] [Article Influence: 28.9] [Reference Citation Analysis]
Number Citing Articles
1 Ge O, Huang A, Wang X, Chen Y, Ye Y, Schomburg L. PALB2 upregulation is associated with a poor prognosis in pancreatic ductal adenocarcinoma. Oncol Lett 2021;21:224. [PMID: 33613713 DOI: 10.3892/ol.2021.12485] [Reference Citation Analysis]
2 Ushio J, Kanno A, Ikeda E, Ando K, Nagai H, Miwata T, Kawasaki Y, Tada Y, Yokoyama K, Numao N, Tamada K, Lefor AK, Yamamoto H. Pancreatic Ductal Adenocarcinoma: Epidemiology and Risk Factors. Diagnostics (Basel) 2021;11:562. [PMID: 33804776 DOI: 10.3390/diagnostics11030562] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Wattenberg MM, Asch D, Yu S, O'Dwyer PJ, Domchek SM, Nathanson KL, Rosen MA, Beatty GL, Siegelman ES, Reiss KA. Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation. Br J Cancer 2020;122:333-9. [PMID: 31787751 DOI: 10.1038/s41416-019-0582-7] [Cited by in Crossref: 38] [Cited by in F6Publishing: 28] [Article Influence: 19.0] [Reference Citation Analysis]
4 Park JK, Kim H, Son DS, Kim NKD, Sung YK, Cho M, Lee C, Noh DH, Lee SH, Lee KT, Lee JK, Jang KT, Park WY, Lee KH. Accurate Prognosis Prediction of Pancreatic Ductal Adenocarcinoma Using Integrated Clinico-Genomic Data of Endoscopic Ultrasound-Guided Fine Needle Biopsy. Cancers (Basel) 2021;13:2791. [PMID: 34205170 DOI: 10.3390/cancers13112791] [Reference Citation Analysis]
5 Orth M, Metzger P, Gerum S, Mayerle J, Schneider G, Belka C, Schnurr M, Lauber K. Pancreatic ductal adenocarcinoma: biological hallmarks, current status, and future perspectives of combined modality treatment approaches. Radiat Oncol 2019;14:141. [PMID: 31395068 DOI: 10.1186/s13014-019-1345-6] [Cited by in Crossref: 74] [Cited by in F6Publishing: 61] [Article Influence: 37.0] [Reference Citation Analysis]
6 Ducreux M, Seufferlein T, Van Laethem JL, Laurent-Puig P, Smolenschi C, Malka D, Boige V, Hollebecque A, Conroy T. Systemic treatment of pancreatic cancer revisited. Semin Oncol 2019;46:28-38. [PMID: 30638624 DOI: 10.1053/j.seminoncol.2018.12.003] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 8.7] [Reference Citation Analysis]
7 Gupta M, Iyer R, Fountzilas C. Poly(ADP-Ribose) Polymerase Inhibitors in Pancreatic Cancer: A New Treatment Paradigms and Future Implications. Cancers (Basel) 2019;11:E1980. [PMID: 31835379 DOI: 10.3390/cancers11121980] [Cited by in Crossref: 18] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
8 Varghese AM, Lowery MA, Yu KH, O'Reilly EM. Current management and future directions in metastatic pancreatic adenocarcinoma. Cancer 2016;122:3765-75. [PMID: 27649047 DOI: 10.1002/cncr.30342] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
9 Liu B, Fu T, He P, Du C, Xu K. Construction of a five-gene prognostic model based on immune-related genes for the prediction of survival in pancreatic cancer. Biosci Rep 2021;41:BSR20204301. [PMID: 34143198 DOI: 10.1042/BSR20204301] [Reference Citation Analysis]
10 Rebelatto TF, Falavigna M, Pozzari M, Spada F, Cella CA, Laffi A, Pellicori S, Fazio N. Should platinum-based chemotherapy be preferred for germline BReast CAncer genes (BRCA) 1 and 2-mutated pancreatic ductal adenocarcinoma (PDAC) patients? A systematic review and meta-analysis. Cancer Treat Rev 2019;80:101895. [PMID: 31542591 DOI: 10.1016/j.ctrv.2019.101895] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
11 Reiss KA, Yu S, Judy R, Symecko H, Nathanson KL, Domchek SM. Retrospective Survival Analysis of Patients With Advanced Pancreatic Ductal Adenocarcinoma and Germline BRCA or PALB2 Mutations. JCO Precision Oncology 2018. [DOI: 10.1200/po.17.00152] [Cited by in Crossref: 9] [Article Influence: 3.0] [Reference Citation Analysis]
12 Hall JC, Marlow LA, Mathias AC, Dawson LK, Durham WF, Meshaw KA, Mullin RJ, Synnott AJ, Small DL, Krishna M, von Hoff D, Schüler J, Hart SN, Couch FJ, Colon-Otero G, Copland JA. Novel patient-derived xenograft mouse model for pancreatic acinar cell carcinoma demonstrates single agent activity of oxaliplatin. J Transl Med 2016;14:129. [PMID: 27165126 DOI: 10.1186/s12967-016-0875-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
13 Singh RR, Goldberg J, Varghese AM, Yu KH, Park W, O'Reilly EM. Genomic profiling in pancreatic ductal adenocarcinoma and a pathway towards therapy individualization: A scoping review. Cancer Treat Rev 2019;75:27-38. [PMID: 30927677 DOI: 10.1016/j.ctrv.2019.03.003] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 10.0] [Reference Citation Analysis]
14 Sharma MB, Carus A, Sunde L, Hamilton-dutoit S, Ladekarl M. BRCA-associated pancreatico-biliary neoplasms: Four cases illustrating the emerging clinical impact of genotyping. Acta Oncologica 2016;55:377-81. [DOI: 10.3109/0284186x.2015.1044023] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
15 Kondo T, Kanai M, Kou T, Sakuma T, Mochizuki H, Kamada M, Nakatsui M, Uza N, Kodama Y, Masui T, Takaori K, Matsumoto S, Miyake H, Okuno Y, Muto M. Association between homologous recombination repair gene mutations and response to oxaliplatin in pancreatic cancer. Oncotarget 2018;9:19817-25. [PMID: 29731985 DOI: 10.18632/oncotarget.24865] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 11.3] [Reference Citation Analysis]
16 Du C, Qi Y, Zhang Y, Wang Y, Zhao X, Min H, Han X, Lang J, Qin H, Shi Q, Zhang Z, Tian X, Anderson GJ, Zhao Y, Nie G, Yang Y. Epidermal Growth Factor Receptor-Targeting Peptide Nanoparticles Simultaneously Deliver Gemcitabine and Olaparib To Treat Pancreatic Cancer with Breast Cancer 2 ( BRCA2) Mutation. ACS Nano 2018;12:10785-96. [PMID: 30407790 DOI: 10.1021/acsnano.8b01573] [Cited by in Crossref: 31] [Cited by in F6Publishing: 23] [Article Influence: 10.3] [Reference Citation Analysis]
17 Sahin IH, Lowery MA, Stadler ZK, Salo-Mullen E, Iacobuzio-Donahue CA, Kelsen DP, O'Reilly EM. Genomic instability in pancreatic adenocarcinoma: a new step towards precision medicine and novel therapeutic approaches. Expert Rev Gastroenterol Hepatol. 2016;10:893-905. [PMID: 26881472 DOI: 10.1586/17474124.2016.1153424] [Cited by in Crossref: 11] [Cited by in F6Publishing: 17] [Article Influence: 2.2] [Reference Citation Analysis]
18 Wang Y, Lakoma A, Zogopoulos G. Building towards Precision Oncology for Pancreatic Cancer: Real-World Challenges and Opportunities. Genes (Basel) 2020;11:E1098. [PMID: 32967105 DOI: 10.3390/genes11091098] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
19 Pimenta JR, Ueda SKN, Peixoto RD. Excellent Response to Olaparib in a Patient with Metastatic Pancreatic Adenocarcinoma with Germline BRCA1 Mutation after Progression on FOLFIRINOX: Case Report and Literature Review. Case Rep Oncol 2020;13:904-10. [PMID: 32884538 DOI: 10.1159/000508533] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
20 Pihlak R, Weaver JMJ, Valle JW, McNamara MG. Advances in Molecular Profiling and Categorisation of Pancreatic Adenocarcinoma and the Implications for Therapy. Cancers (Basel) 2018;10:E17. [PMID: 29329208 DOI: 10.3390/cancers10010017] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
21 Cloyd JM, Wang H, Egger ME, Tzeng CD, Prakash LR, Maitra A, Varadhachary GR, Shroff R, Javle M, Fogelman D, Wolff RA, Overman MJ, Koay EJ, Das P, Herman JM, Kim MP, Vauthey JN, Aloia TA, Fleming JB, Lee JE, Katz MHG. Association of Clinical Factors With a Major Pathologic Response Following Preoperative Therapy for Pancreatic Ductal Adenocarcinoma. JAMA Surg. 2017;152:1048-1056. [PMID: 28700784 DOI: 10.1001/jamasurg.2017.2227] [Cited by in Crossref: 55] [Cited by in F6Publishing: 53] [Article Influence: 13.8] [Reference Citation Analysis]
22 Lohse I, Borgida A, Cao P, Cheung M, Pintilie M, Bianco T, Holter S, Ibrahimov E, Kumareswaran R, Bristow RG, Tsao MS, Gallinger S, Hedley DW. BRCA1 and BRCA2 mutations sensitize to chemotherapy in patient-derived pancreatic cancer xenografts. Br J Cancer. 2015;113:425-432. [PMID: 26180923 DOI: 10.1038/bjc.2015.220] [Cited by in Crossref: 45] [Cited by in F6Publishing: 41] [Article Influence: 7.5] [Reference Citation Analysis]
23 Hatano Y, Tamada M, Matsuo M, Hara A. Molecular Trajectory of BRCA1 and BRCA2 Mutations. Front Oncol 2020;10:361. [PMID: 32269964 DOI: 10.3389/fonc.2020.00361] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 17.0] [Reference Citation Analysis]
24 Walker EJ, Carnevale J, Pedley C, Blanco A, Chan S, Collisson EA, Tempero MA, Ko AH. Referral frequency, attrition rate, and outcomes of germline testing in patients with pancreatic adenocarcinoma. Fam Cancer 2019;18:241-51. [PMID: 30267352 DOI: 10.1007/s10689-018-0106-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
25 Cloyd JM, Ejaz A, Shen C, Dillhoff M, Williams TM, Noonan A, Pawlik TM, Tsung A. Pathologic complete response following neoadjuvant therapy for pancreatic ductal adenocarcinoma: defining the incidence, predictors, and outcomes. HPB (Oxford). 2020;22:1569-1576. [PMID: 32063480 DOI: 10.1016/j.hpb.2020.01.013] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
26 Khan MA, Azim S, Zubair H, Bhardwaj A, Patel GK, Khushman M, Singh S, Singh AP. Molecular Drivers of Pancreatic Cancer Pathogenesis: Looking Inward to Move Forward. Int J Mol Sci 2017;18:E779. [PMID: 28383487 DOI: 10.3390/ijms18040779] [Cited by in Crossref: 36] [Cited by in F6Publishing: 28] [Article Influence: 9.0] [Reference Citation Analysis]
27 de Mestier L, Danset J, Neuzillet C, Rebours V, Cros J, Soufir N, Hammel P. Pancreatic ductal adenocarcinoma in BRCA2 mutation carriers. Endocrine-Related Cancer 2016;23:T57-67. [DOI: 10.1530/erc-16-0269] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 2.6] [Reference Citation Analysis]
28 Kou T, Kanai M, Yamamoto Y, Kamada M, Nakatsui M, Sakuma T, Mochizuki H, Hiroshima A, Sugiyama A, Nakamura E, Miyake H, Minamiguchi S, Takaori K, Matsumoto S, Haga H, Seno H, Kosugi S, Okuno Y, Muto M. Clinical sequencing using a next-generation sequencing-based multiplex gene assay in patients with advanced solid tumors. Cancer Sci 2017;108:1440-6. [PMID: 28440963 DOI: 10.1111/cas.13265] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 8.0] [Reference Citation Analysis]
29 Golan T, Hammel P, Reni M, Van Cutsem E, Macarulla T, Hall MJ, Park JO, Hochhauser D, Arnold D, Oh DY, Reinacher-Schick A, Tortora G, Algül H, O'Reilly EM, McGuinness D, Cui KY, Schlienger K, Locker GY, Kindler HL. Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. N Engl J Med 2019;381:317-27. [PMID: 31157963 DOI: 10.1056/NEJMoa1903387] [Cited by in Crossref: 553] [Cited by in F6Publishing: 284] [Article Influence: 276.5] [Reference Citation Analysis]
30 Rainone M, Singh I, Salo-Mullen EE, Stadler ZK, O'Reilly EM. An Emerging Paradigm for Germline Testing in Pancreatic Ductal Adenocarcinoma and Immediate Implications for Clinical Practice: A Review. JAMA Oncol. 2020;6:764-771. [PMID: 32053139 DOI: 10.1001/jamaoncol.2019.5963] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
31 Choi YH, Lim Y, Ryu JK, Paik WH, Lee SH, Kim YT, Kim JH. Excision Repair Cross-Complementation Group 6 Gene Polymorphism Is Associated with the Response to FOLFIRINOX Chemotherapy in Asian Patients with Pancreatic Cancer. Cancers (Basel) 2021;13:1196. [PMID: 33801891 DOI: 10.3390/cancers13061196] [Reference Citation Analysis]
32 Tsujie M, Fumita S, Wakasa T, Mizuno S, Ishikawa H, Kitani K, Satoi S, Okada K, Inoue K, Fukuda S, Manabe H, Ichimura N, Ueda S, Tamura T, Kawasaki T, Yukawa M, Ohta Y, Inoue M. A Case of Pathological Complete Response Following FOLFIRINOX Therapy for Pancreatic Adenocarcinoma with Synchronous Distant Lymph Node Metastases. Int J Surg Case Rep 2020;72:471-6. [PMID: 32698268 DOI: 10.1016/j.ijscr.2020.06.044] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
33 Luo G, Lu Y, Jin K, Cheng H, Guo M, Liu Z, Long J, Liu C, Ni Q, Yu X. Pancreatic cancer: BRCA mutation and personalized treatment. Expert Rev Anticancer Ther 2015;15:1223-31. [PMID: 26402249 DOI: 10.1586/14737140.2015.1086271] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 3.8] [Reference Citation Analysis]
34 Kim SH, Hwang HK, Lee WJ, Kang CM. Biologic behavior of resected BRCA-mutated pancreatic cancer: Comparison with sporadic pancreatic cancer and other BRCA-related cancers. Pancreatology 2021;21:544-9. [PMID: 33612442 DOI: 10.1016/j.pan.2021.02.007] [Reference Citation Analysis]
35 Rosen MN, Goodwin RA, Vickers MM. BRCA mutated pancreatic cancer: A change is coming. World J Gastroenterol 2021;27:1943-58. [PMID: 34007132 DOI: 10.3748/wjg.v27.i17.1943] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
36 Singhi AD, George B, Greenbowe JR, Chung J, Suh J, Maitra A, Klempner SJ, Hendifar A, Milind JM, Golan T, Brand RE, Zureikat AH, Roy S, Schrock AB, Miller VA, Ross JS, Ali SM, Bahary N. Real-Time Targeted Genome Profile Analysis of Pancreatic Ductal Adenocarcinomas Identifies Genetic Alterations That Might Be Targeted With Existing Drugs or Used as Biomarkers. Gastroenterology 2019;156:2242-2253.e4. [DOI: 10.1053/j.gastro.2019.02.037] [Cited by in Crossref: 81] [Cited by in F6Publishing: 69] [Article Influence: 40.5] [Reference Citation Analysis]
37 Glatzer M, Horber D, Montemurro M, Winterhalder R, Inauen R, Berger MD, Pestalozzi B, Pederiva S, Pless M, Putora PM. Choice of first line systemic treatment in pancreatic cancer among national experts. Pancreatology 2020;20:686-90. [PMID: 32299764 DOI: 10.1016/j.pan.2020.03.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
38 Zhou J, Kang Y, Chen L, Wang H, Liu J, Zeng S, Yu L. The Drug-Resistance Mechanisms of Five Platinum-Based Antitumor Agents. Front Pharmacol. 2020;11:343. [PMID: 32265714 DOI: 10.3389/fphar.2020.00343] [Cited by in Crossref: 37] [Cited by in F6Publishing: 29] [Article Influence: 37.0] [Reference Citation Analysis]
39 Holter S, Borgida A, Dodd A, Grant R, Semotiuk K, Hedley D, Dhani N, Narod S, Akbari M, Moore M, Gallinger S. Germline BRCA Mutations in a Large Clinic-Based Cohort of Patients With Pancreatic Adenocarcinoma. J Clin Oncol. 2015;33:3124-3129. [PMID: 25940717 DOI: 10.1200/jco.2014.59.7401] [Cited by in Crossref: 212] [Cited by in F6Publishing: 111] [Article Influence: 35.3] [Reference Citation Analysis]
40 Heeke AL, Pishvaian MJ, Lynce F, Xiu J, Brody JR, Chen WJ, Baker TM, Marshall JL, Isaacs C. Prevalence of Homologous Recombination-Related Gene Mutations Across Multiple Cancer Types. JCO Precis Oncol 2018;2018. [PMID: 30234181 DOI: 10.1200/PO.17.00286] [Cited by in Crossref: 56] [Cited by in F6Publishing: 64] [Article Influence: 18.7] [Reference Citation Analysis]
41 Yuan F, Zhang YH, Wan S, Wang S, Kong XY. Mining for Candidate Genes Related to Pancreatic Cancer Using Protein-Protein Interactions and a Shortest Path Approach. Biomed Res Int 2015;2015:623121. [PMID: 26613085 DOI: 10.1155/2015/623121] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
42 Hann A, Bohle W, Egger J, Zoller W. Feasibility of alternating induction and maintenance chemotherapy in pancreatic cancer. Sci Rep 2017;7:41549. [PMID: 28139684 DOI: 10.1038/srep41549] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
43 Okano N, Morizane C, Nomura S, Takahashi H, Tsumura H, Satake H, Mizuno N, Tsuji K, Shioji K, Asagi A, Yasui K, Kitagawa S, Kashiwada T, Ishiguro A, Kanai M, Ueno M, Ogura T, Shimizu S, Tobimatsu K, Motoya M, Nakashima K, Ikeda M, Okusaka T, Furuse J. Phase II clinical trial of gemcitabine plus oxaliplatin in patients with metastatic pancreatic adenocarcinoma with a family history of pancreatic/breast/ovarian/prostate cancer or personal history of breast/ovarian/prostate cancer (FABRIC study). Int J Clin Oncol 2020;25:1835-43. [PMID: 32535711 DOI: 10.1007/s10147-020-01721-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
44 Halpern N, Grinshpun A, Boursi B, Golan T, Margalit O, Aderka D, Friedman E, Laitman Y, Hubert A, Kadouri L, Hamburger T, Barnes-Kedar I, Levi Z, Ben-Aharon I, Brenner B, Goldberg Y, Peretz T, Shacham-Shmueli E. Clinical Characteristics and Prognosis of Gastric Cancer Patients with BRCA 1/2 Germline Mutations: Report of Ten Cases and a Literature Review. Onco Targets Ther. 2020;13:11637-11644. [PMID: 33235458 DOI: 10.2147/ott.s276814] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
45 Momtaz P, O'Connor CA, Chou JF, Capanu M, Park W, Bandlamudi C, Berger MF, Kelsen DP, Suehnholz SP, Chakravarty D, Yu KH, Varghese AM, Zervoudakis A, Li J, Ku GY, Park JS, Shcherba M, Harding JJ, Goldberg Z, Abou-Alfa GK, Salo-Mullen EE, Stadler ZK, Iacobuzio-Donahue CA, O'Reilly EM. Pancreas cancer and BRCA: A critical subset of patients with improving therapeutic outcomes. Cancer 2021. [PMID: 34351646 DOI: 10.1002/cncr.33812] [Reference Citation Analysis]
46 Martinez-Useros J, Garcia-Foncillas J. The Role of BRCA2 Mutation Status as Diagnostic, Predictive, and Prognosis Biomarker for Pancreatic Cancer. Biomed Res Int 2016;2016:1869304. [PMID: 28078281 DOI: 10.1155/2016/1869304] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
47 Waddell N, Pajic M, Patch AM, Chang DK, Kassahn KS, Bailey P, Johns AL, Miller D, Nones K, Quek K. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature. 2015;518:495-501. [PMID: 25719666 DOI: 10.1038/nature14169] [Cited by in Crossref: 1379] [Cited by in F6Publishing: 1157] [Article Influence: 229.8] [Reference Citation Analysis]
48 Sahin IH, Iacobuzio-Donahue CA, O’Reilly EM. Molecular signature of pancreatic adenocarcinoma: an insight from genotype to phenotype and challenges for targeted therapy. Expert Opin Ther Targets. 2016;20:341-359. [PMID: 26439702 DOI: 10.1517/14728222.2016.1094057] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 3.7] [Reference Citation Analysis]
49 Chand S, O'Hayer K, Blanco FF, Winter JM, Brody JR. The Landscape of Pancreatic Cancer Therapeutic Resistance Mechanisms. Int J Biol Sci 2016;12:273-82. [PMID: 26929734 DOI: 10.7150/ijbs.14951] [Cited by in Crossref: 57] [Cited by in F6Publishing: 54] [Article Influence: 11.4] [Reference Citation Analysis]
50 Yu IS, Cheung WY. A Contemporary Review of the Treatment Landscape and the Role of Predictive and Prognostic Biomarkers in Pancreatic Adenocarcinoma. Can J Gastroenterol Hepatol 2018;2018:1863535. [PMID: 29623263 DOI: 10.1155/2018/1863535] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
51 Pandey N, Black BE. Rapid Detection and Signaling of DNA Damage by PARP-1. Trends Biochem Sci 2021;46:744-57. [PMID: 33674152 DOI: 10.1016/j.tibs.2021.01.014] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
52 Lundberg J, Reardon J, Blazer M, Phillips G, Bekaii-Saab T. Biweekly gemcitabine and low-dose cisplatin in the treatment of locally advanced or metastatic pancreatic cancer patients: a single institute experience. Med Oncol 2016;33:4. [PMID: 26696390 DOI: 10.1007/s12032-015-0720-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
53 Reiss KA, Mick R, O'Hara MH, Teitelbaum U, Karasic TB, Schneider C, Cowden S, Southwell T, Romeo J, Izgur N, Hannan ZM, Tondon R, Nathanson K, Vonderheide RH, Wattenberg MM, Beatty G, Domchek SM. Phase II Study of Maintenance Rucaparib in Patients With Platinum-Sensitive Advanced Pancreatic Cancer and a Pathogenic Germline or Somatic Variant in BRCA1, BRCA2, or PALB2. J Clin Oncol 2021;39:2497-505. [PMID: 33970687 DOI: 10.1200/JCO.21.00003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
54 Zhan W, Shelton CA, Greer PJ, Brand RE, Whitcomb DC. Germline Variants and Risk for Pancreatic Cancer: A Systematic Review and Emerging Concepts. Pancreas 2018;47:924-36. [PMID: 30113427 DOI: 10.1097/MPA.0000000000001136] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
55 Salo-Mullen EE, O'Reilly EM, Kelsen DP, Ashraf AM, Lowery MA, Yu KH, Reidy DL, Epstein AS, Lincoln A, Saldia A, Jacobs LM, Rau-Murthy R, Zhang L, Kurtz RC, Saltz L, Offit K, Robson ME, Stadler ZK. Identification of germline genetic mutations in patients with pancreatic cancer. Cancer. 2015;121:4382-4388. [PMID: 26440929 DOI: 10.1002/cncr.29664] [Cited by in Crossref: 103] [Cited by in F6Publishing: 85] [Article Influence: 17.2] [Reference Citation Analysis]
56 Perkhofer L, Gout J, Roger E, Kude de Almeida F, Baptista Simões C, Wiesmüller L, Seufferlein T, Kleger A. DNA damage repair as a target in pancreatic cancer: state-of-the-art and future perspectives. Gut 2021;70:606-17. [PMID: 32855305 DOI: 10.1136/gutjnl-2019-319984] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 20.0] [Reference Citation Analysis]
57 Corrias G, Raeside MC, Agostini A, Huicochea-Castellanos S, Aramburu-Nunez D, Paudyal R, Shukla-Dave A, Smelianskaia O, Capanu M, Zheng J, Fung M, Kelsen DP, Mangino DA, Robson ME, Goldfrank DJ, Carter J, Allen PJ, Conti B, Monti S, Do RKG, Mannelli L. Pilot study of rapid MR pancreas screening for patients with BRCA mutation. Eur Radiol 2019;29:3976-85. [PMID: 30689033 DOI: 10.1007/s00330-018-5975-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
58 Pokataev I, Fedyanin M, Polyanskaya E, Popova A, Agafonova J, Menshikova S, Tryakin A, Rumyantsev A, Tjulandin S. Efficacy of platinum-based chemotherapy and prognosis of patients with pancreatic cancer with homologous recombination deficiency: comparative analysis of published clinical studies. ESMO Open 2020;5:e000578. [PMID: 33551067 DOI: 10.1136/esmoopen-2019-000578] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
59 Crowley F, Park W, O'Reilly EM. Targeting DNA damage repair pathways in pancreas cancer. Cancer Metastasis Rev 2021. [PMID: 34403012 DOI: 10.1007/s10555-021-09983-1] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
60 Lemstrova R, Melichar B, Mohelnikova-duchonova B. Therapeutic potential of taxanes in the treatment of metastatic pancreatic cancer. Cancer Chemother Pharmacol 2016;78:1101-11. [DOI: 10.1007/s00280-016-3058-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
61 Carnevale J, Ashworth A. Assessing the Significance of BRCA1 and BRCA2 Mutations in Pancreatic Cancer. J Clin Oncol 2015;33:3080-1. [PMID: 25987697 DOI: 10.1200/JCO.2015.61.6961] [Cited by in Crossref: 27] [Cited by in F6Publishing: 13] [Article Influence: 4.5] [Reference Citation Analysis]
62 Kardosh A, Lichtensztajn DY, Gubens MA, Kunz PL, Fisher GA, Clarke CA. Long-Term Survivors of Pancreatic Cancer: A California Population-Based Study. Pancreas 2018;47:958-66. [PMID: 30074526 DOI: 10.1097/MPA.0000000000001133] [Cited by in Crossref: 22] [Cited by in F6Publishing: 14] [Article Influence: 11.0] [Reference Citation Analysis]
63 Barnett D, Liu Y, Partyka K, Huang Y, Tang H, Hostetter G, Brand RE, Singhi AD, Drake RR, Haab BB. The CA19-9 and Sialyl-TRA Antigens Define Separate Subpopulations of Pancreatic Cancer Cells. Sci Rep. 2017;7:4020. [PMID: 28642461 DOI: 10.1038/s41598-017-04164-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
64 Huang X, Wang C, Ma T, Huang Z, Zhou H, Xu L, Zhang R, Zhao J, Zhang Y, Huang Z, Shao L, Wang Y, Yang F, Che X. The Efficacy of Combined Cisplatin and Nanoparticle Albumin-Bound Paclitaxel in a Stage IV Pancreatic Squamous Cell Carcinoma Patient With a Somatic BRCA2 Mutation: A Case Report. Front Oncol 2021;11:585983. [PMID: 33996534 DOI: 10.3389/fonc.2021.585983] [Reference Citation Analysis]
65 Toss A, Venturelli M, Molinaro E, Pipitone S, Barbieri E, Marchi I, Tenedini E, Artuso L, Castellano S, Marino M, Tagliafico E, Razzaboni E, De Matteis E, Cascinu S, Cortesi L. Hereditary Pancreatic Cancer: A Retrospective Single-Center Study of 5143 Italian Families with History of BRCA-Related Malignancies. Cancers (Basel) 2019;11:E193. [PMID: 30736435 DOI: 10.3390/cancers11020193] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
66 Lai E, Ziranu P, Spanu D, Dubois M, Pretta A, Tolu S, Camera S, Liscia N, Mariani S, Persano M, Migliari M, Donisi C, Demurtas L, Pusceddu V, Puzzoni M, Scartozzi M. BRCA-mutant pancreatic ductal adenocarcinoma. Br J Cancer 2021. [PMID: 34262146 DOI: 10.1038/s41416-021-01469-9] [Reference Citation Analysis]
67 Di Marco M, Carloni R, De Lorenzo S, Mosconi C, Palloni A, Grassi E, Filippini DM, Ricci AD, Rizzo A, Di Federico A, Santini D, Turchetti D, Ricci C, Ingaldi C, Alberici L, Minni F, Golfieri R, Brandi G, Casadei R. Pancreatic mucinous cystadenocarcinoma in a patient harbouring BRCA1 germline mutation effectively treated with olaparib: A case report. World J Gastrointest Oncol 2020;12:1456-63. [PMID: 33362915 DOI: 10.4251/wjgo.v12.i12.1456] [Cited by in CrossRef: 1] [Article Influence: 1.0] [Reference Citation Analysis]
68 Andrei A, Hall A, Smith AL, Bascuñana C, Malina A, Connor A, Altinel-omeroglu G, Huang S, Pelletier J, Huntsman D, Gallinger S, Omeroglu A, Metrakos P, Zogopoulos G. Increased in vitro and in vivo sensitivity of BRCA2-associated pancreatic cancer to the poly(ADP-ribose) polymerase-1/2 inhibitor BMN 673. Cancer Letters 2015;364:8-16. [DOI: 10.1016/j.canlet.2015.04.003] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.7] [Reference Citation Analysis]
69 Ohmoto A, Yachida S, Morizane C. Genomic Features and Clinical Management of Patients with Hereditary Pancreatic Cancer Syndromes and Familial Pancreatic Cancer. Int J Mol Sci. 2019;20. [PMID: 30699894 DOI: 10.3390/ijms20030561] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 7.0] [Reference Citation Analysis]
70 Xu JZ, Wang WQ, Zhang SR, Xu HX, Wu CT, Qi ZH, Gao HL, Li S, Ni QX, Yu XJ, Liu L. Neoadjuvant Therapy is Essential for Resectable Pancreatic Cancer. Curr Med Chem. 2019;26:7196-7211. [PMID: 29651946 DOI: 10.2174/0929867325666180413101722] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
71 Verdaguer H, Arroyo A, Macarulla T. New Horizons in the Treatment of Metastatic Pancreatic Cancer: A Review of the Key Biology Features and the Most Recent Advances to Treat Metastatic Pancreatic Cancer. Targ Oncol 2018;13:691-704. [DOI: 10.1007/s11523-018-0609-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
72 Martens S, Lefesvre P, Nicolle R, Biankin A, Puleo F, Van Laethem J, Rooman I. Different shades of pancreatic ductal adenocarcinoma, different paths towards precision therapeutic applications. Annals of Oncology 2019;30:1428-36. [DOI: 10.1093/annonc/mdz181] [Cited by in Crossref: 23] [Cited by in F6Publishing: 12] [Article Influence: 11.5] [Reference Citation Analysis]
73 Smith AL, Wong C, Cuggia A, Borgida A, Holter S, Hall A, Connor AA, Bascuñana C, Asselah J, Bouganim N, Poulin V, Jolivet J, Vafiadis P, Le P, Martel G, Lemay F, Beaudoin A, Rafatzand K, Chaudhury P, Barkun J, Metrakos P, Marcus V, Omeroglu A, Chong G, Akbari MR, Foulkes WD, Gallinger S, Zogopoulos G. Reflex Testing for Germline BRCA1 , BRCA2 , PALB2 , and ATM Mutations in Pancreatic Cancer: Mutation Prevalence and Clinical Outcomes From Two Canadian Research Registries. JCO Precision Oncology 2018. [DOI: 10.1200/po.17.00098] [Cited by in Crossref: 8] [Article Influence: 2.7] [Reference Citation Analysis]
74 Hu HF, Ye Z, Qin Y, Xu XW, Yu XJ, Zhuo QF, Ji SR. Mutations in key driver genes of pancreatic cancer: molecularly targeted therapies and other clinical implications. Acta Pharmacol Sin 2021. [PMID: 33574569 DOI: 10.1038/s41401-020-00584-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
75 Bhosale P, Cox V, Faria S, Javadi S, Viswanathan C, Koay E, Tamm E. Genetics of pancreatic cancer and implications for therapy. Abdom Radiol 2018;43:404-14. [DOI: 10.1007/s00261-017-1394-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
76 Vaishampayan UN. An evaluation of olaparib for the treatment of pancreatic cancer. Expert Opin Pharmacother 2021;22:521-6. [PMID: 33094666 DOI: 10.1080/14656566.2020.1837113] [Reference Citation Analysis]
77 Zhang X, Ni Z, Duan Z, Xin Z, Wang H, Tan J, Wang G, Li F. Overexpression of E2F mRNAs associated with gastric cancer progression identified by the transcription factor and miRNA co-regulatory network analysis. PLoS One 2015;10:e0116979. [PMID: 25646628 DOI: 10.1371/journal.pone.0116979] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 4.8] [Reference Citation Analysis]
78 Baselga J, Bhardwaj N, Cantley LC, DeMatteo R, DuBois RN, Foti M, Gapstur SM, Hahn WC, Helman LJ, Jensen RA, Paskett ED, Lawrence TS, Lutzker SG, Szabo E. AACR Cancer Progress Report 2015. Clin Cancer Res 2015;21:S1-128. [PMID: 26429991 DOI: 10.1158/1078-0432.CCR-15-1846] [Cited by in Crossref: 20] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
79 McIntyre CA, Lawrence SA, Richards AL, Chou JF, Wong W, Capanu M, Berger MF, Donoghue MTA, Yu KH, Varghese AM, Kelsen DP, Park W, Balachandran VP, Kingham TP, D'Angelica MI, Drebin JA, Jarnagin WR, Iacobuzio-Donahue CA, Allen PJ, O'Reilly EM. Alterations in driver genes are predictive of survival in patients with resected pancreatic ductal adenocarcinoma. Cancer 2020;126:3939-49. [PMID: 32573775 DOI: 10.1002/cncr.33038] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
80 Elsayed M, Abdelrahim M. The Latest Advancement in Pancreatic Ductal Adenocarcinoma Therapy: A Review Article for the Latest Guidelines and Novel Therapies. Biomedicines 2021;9:389. [PMID: 33917380 DOI: 10.3390/biomedicines9040389] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
81 Navarro EB, López EV, Quijano Y, Caruso R, Ferri V, Durand H, Cabrera IF, Reques ED, Ielpo B, Glagolieva AY, Plaza C. Impact of BRCA1/2 gene mutations on survival of patients with pancreatic cancer: A case-series analysis. Ann Hepatobiliary Pancreat Surg 2019;23:200-5. [PMID: 31225426 DOI: 10.14701/ahbps.2019.23.2.200] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
82 Tatarian T, Winter JM. Genetics of Pancreatic Cancer and Its Implications on Therapy. Surgical Clinics of North America 2016;96:1207-21. [DOI: 10.1016/j.suc.2016.07.014] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
83 Ciernikova S, Earl J, García Bermejo ML, Stevurkova V, Carrato A, Smolkova B. Epigenetic Landscape in Pancreatic Ductal Adenocarcinoma: On the Way to Overcoming Drug Resistance? Int J Mol Sci 2020;21:E4091. [PMID: 32521716 DOI: 10.3390/ijms21114091] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
84 Kowalewski A, Szylberg Ł, Saganek M, Napiontek W, Antosik P, Grzanka D. Emerging strategies in BRCA-positive pancreatic cancer. J Cancer Res Clin Oncol 2018;144:1503-7. [PMID: 29777302 DOI: 10.1007/s00432-018-2666-9] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 8.7] [Reference Citation Analysis]
85 Zhang SY, Zhang SQ, Nagaraju GP, El-rayes BF. Biomarkers for personalized medicine in GI cancers. Molecular Aspects of Medicine 2015;45:14-27. [DOI: 10.1016/j.mam.2015.06.002] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
86 Pihlak R, Valle JW, McNamara MG. Germline mutations in pancreatic cancer and potential new therapeutic options. Oncotarget. 2017;8:73240-73257. [PMID: 29069866 DOI: 10.18632/oncotarget.17291] [Cited by in Crossref: 32] [Cited by in F6Publishing: 22] [Article Influence: 8.0] [Reference Citation Analysis]
87 Stošić B, Janković R, Stošić M, Marković D, Veselinović I, Ilić I, Sokolović D. Caffeic acid phenethyl ester attenuates changes in pancreatic tissue damage biomarkers induced by cisplatin. Can J Physiol Pharmacol 2020;98:296-303. [DOI: 10.1139/cjpp-2019-0374] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
88 Golan T, Sella T, O'Reilly EM, Katz MH, Epelbaum R, Kelsen DP, Borgida A, Maynard H, Kindler H, Friedmen E, Javle M, Gallinger S. Overall survival and clinical characteristics of BRCA mutation carriers with stage I/II pancreatic cancer. Br J Cancer 2017;116:697-702. [PMID: 28183138 DOI: 10.1038/bjc.2017.19] [Cited by in Crossref: 41] [Cited by in F6Publishing: 33] [Article Influence: 10.3] [Reference Citation Analysis]
89 Teo MY, O'Reilly EM. Is it time to split strategies to treat homologous recombinant deficiency in pancreas cancer? J Gastrointest Oncol 2016;7:738-49. [PMID: 27747088 DOI: 10.21037/jgo.2016.05.04] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
90 Javle M, Golan T, Maitra A. Changing the course of pancreatic cancer--Focus on recent translational advances. Cancer Treat Rev 2016;44:17-25. [PMID: 26924195 DOI: 10.1016/j.ctrv.2016.01.004] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
91 Wang S, Bager CL, Karsdal MA, Chondros D, Taverna D, Willumsen N. Blood-based extracellular matrix biomarkers as predictors of survival in patients with metastatic pancreatic ductal adenocarcinoma receiving pegvorhyaluronidase alfa. J Transl Med 2021;19:39. [PMID: 33478521 DOI: 10.1186/s12967-021-02701-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
92 Traub B, Link KH, Kornmann M. Curing pancreatic cancer. Semin Cancer Biol 2021:S1044-579X(21)00160-7. [PMID: 34062264 DOI: 10.1016/j.semcancer.2021.05.030] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
93 Lai E, Puzzoni M, Ziranu P, Pretta A, Impera V, Mariani S, Liscia N, Soro P, Musio F, Persano M, Donisi C, Tolu S, Balconi F, Pireddu A, Demurtas L, Pusceddu V, Camera S, Sclafani F, Scartozzi M. New therapeutic targets in pancreatic cancer. Cancer Treat Rev 2019;81:101926. [PMID: 31739115 DOI: 10.1016/j.ctrv.2019.101926] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 16.0] [Reference Citation Analysis]
94 Wong W, Raufi AG, Safyan RA, Bates SE, Manji GA. BRCA Mutations in Pancreas Cancer: Spectrum, Current Management, Challenges and Future Prospects. Cancer Manag Res. 2020;12:2731-2742. [PMID: 32368150 DOI: 10.2147/cmar.s211151] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 11.0] [Reference Citation Analysis]
95 Napolitano F, Formisano L, Giardino A, Girelli R, Servetto A, Santaniello A, Foschini F, Marciano R, Mozzillo E, Carratù AC, Cascetta P, De Placido P, De Placido S, Bianco R. Neoadjuvant Treatment in Locally Advanced Pancreatic Cancer (LAPC) Patients with FOLFIRINOX or Gemcitabine NabPaclitaxel: A Single-Center Experience and a Literature Review. Cancers (Basel) 2019;11:E981. [PMID: 31337045 DOI: 10.3390/cancers11070981] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]
96 Baines A, Martin P, Rorie C. Current and Emerging Targeting Strategies for Treatment of Pancreatic Cancer. Molecular and Cellular Changes in the Cancer Cell. Elsevier; 2016. pp. 277-320. [DOI: 10.1016/bs.pmbts.2016.09.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
97 Freitas AC, Opinião A, Fragoso S, Nunes H, Santos M, Clara A, Bento S, Luis A, Silva J, Moura C, Filipe B, Machado P, Santos S, André S, Rodrigues P, Parreira J, Vaz F. Men seeking counselling in a Breast Cancer Risk Evaluation Clinic. Ecancermedicalscience 2018;12:804. [PMID: 29456621 DOI: 10.3332/ecancer.2018.804] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
98 Peters MLB, Tseng JF, Miksad RA. Genetic Testing in Pancreatic Ductal Adenocarcinoma: Implications for Prevention and Treatment. Clinical Therapeutics 2016;38:1622-35. [DOI: 10.1016/j.clinthera.2016.03.006] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
99 Chiaravalli M, Reni M, O'reilly EM. Pancreatic ductal adenocarcinoma: State-of-the-art 2017 and new therapeutic strategies. Cancer Treatment Reviews 2017;60:32-43. [DOI: 10.1016/j.ctrv.2017.08.007] [Cited by in Crossref: 76] [Cited by in F6Publishing: 74] [Article Influence: 19.0] [Reference Citation Analysis]
100 Ruffalo M, Thomas R, Chen J, Lee AV, Oesterreich S, Bar-Joseph Z. Network-guided prediction of aromatase inhibitor response in breast cancer. PLoS Comput Biol 2019;15:e1006730. [PMID: 30742607 DOI: 10.1371/journal.pcbi.1006730] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
101 Shimmura H, Kuramochi H, Jibiki N, Katagiri S, Nishino T, Araida T. Dramatic response of FOLFIRINOX regimen in a collision pancreatic adenocarcinoma patient with a germline BRCA2 mutation: a case report. Jpn J Clin Oncol 2019;49:1049-54. [PMID: 31612916 DOI: 10.1093/jjco/hyz141] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
102 Lee B, Hutchinson R, Wong HL, Tie J, Putoczki T, Tran B, Gibbs P, Christie M. Emerging biomarkers for immunomodulatory cancer treatment of upper gastrointestinal, pancreatic and hepatic cancers. Semin Cancer Biol. 2018;52:241-252. [PMID: 29258858 DOI: 10.1016/j.semcancer.2017.12.009] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
103 Patel H, Okamura R, Fanta P, Patel C, Lanman RB, Raymond VM, Kato S, Kurzrock R. Clinical correlates of blood-derived circulating tumor DNA in pancreatic cancer. J Hematol Oncol. 2019;12:130. [PMID: 31801585 DOI: 10.1186/s13045-019-0824-4] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 10.0] [Reference Citation Analysis]
104 Dell'Aquila E, Fulgenzi CAM, Minelli A, Citarella F, Stellato M, Pantano F, Russano M, Cursano MC, Napolitano A, Zeppola T, Vincenzi B, Tonini G, Santini D. Prognostic and predictive factors in pancreatic cancer. Oncotarget 2020;11:924-41. [PMID: 32206189 DOI: 10.18632/oncotarget.27518] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 14.0] [Reference Citation Analysis]
105 Lee K, Yoo C, Kim KP, Park KJ, Chang HM, Kim TW, Lee JL, Lee W, Lee SS, Park DH, Song TJ, Seo DW, Lee SK, Kim MH, Shin SH, Hwang DW, Song KB, Lee JH, Kim SC, Ryoo BY. Germline BRCA mutations in Asian patients with pancreatic adenocarcinoma: a prospective study evaluating risk category for genetic testing. Invest New Drugs 2018;36:163-9. [PMID: 28782087 DOI: 10.1007/s10637-017-0497-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
106 Iyer G, Balar AV, Milowsky MI, Bochner BH, Dalbagni G, Donat SM, Herr HW, Huang WC, Taneja SS, Woods M, Ostrovnaya I, Al-Ahmadie H, Arcila ME, Riches JC, Meier A, Bourque C, Shady M, Won H, Rose TL, Kim WY, Kania BE, Boyd ME, Cipolla CK, Regazzi AM, Delbeau D, McCoy AS, Vargas HA, Berger MF, Solit DB, Rosenberg JE, Bajorin DF. Multicenter Prospective Phase II Trial of Neoadjuvant Dose-Dense Gemcitabine Plus Cisplatin in Patients With Muscle-Invasive Bladder Cancer. J Clin Oncol 2018;36:1949-56. [PMID: 29742009 DOI: 10.1200/JCO.2017.75.0158] [Cited by in Crossref: 63] [Cited by in F6Publishing: 19] [Article Influence: 21.0] [Reference Citation Analysis]
107 Neesse A, Bauer CA, Öhlund D, Lauth M, Buchholz M, Michl P, Tuveson DA, Gress TM. Stromal biology and therapy in pancreatic cancer: ready for clinical translation? Gut 2019;68:159-71. [PMID: 30177543 DOI: 10.1136/gutjnl-2018-316451] [Cited by in Crossref: 104] [Cited by in F6Publishing: 88] [Article Influence: 34.7] [Reference Citation Analysis]
108 Martínez-galán J, Rodriguez I, Caba O. Importance of BRCA mutation for the current treatment of pancreatic cancer beyond maintenance. WJG 2021;27:6515-21. [DOI: 10.3748/wjg.v27.i39.6515] [Reference Citation Analysis]
109 Tesfaye AA, Kamgar M, Azmi A, Philip PA. The evolution into personalized therapies in pancreatic ductal adenocarcinoma: challenges and opportunities. Expert Rev Anticancer Ther. 2018;18:131-148. [PMID: 29254387 DOI: 10.1080/14737140.2018.1417844] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
110 Giri B, Sethi V, Dudeja V, Banerjee S, Livingstone A, Saluja A. Genetics of pancreatic cyst-cancer progression: standing on the shoulders of giants. Curr Opin Gastroenterol 2017;33:404-10. [PMID: 28682795 DOI: 10.1097/MOG.0000000000000382] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
111 Connor AA, Gallinger S. Hereditary Pancreatic Cancer Syndromes. Surg Oncol Clin N Am. 2015;24:733-764. [PMID: 26363539 DOI: 10.1016/j.soc.2015.06.007] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 3.8] [Reference Citation Analysis]
112 O'Reilly EM, Lee JW, Zalupski M, Capanu M, Park J, Golan T, Tahover E, Lowery MA, Chou JF, Sahai V, Brenner R, Kindler HL, Yu KH, Zervoudakis A, Vemuri S, Stadler ZK, Do RKG, Dhani N, Chen AP, Kelsen DP. Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline BRCA/PALB2 Mutation. J Clin Oncol 2020;38:1378-88. [PMID: 31976786 DOI: 10.1200/JCO.19.02931] [Cited by in Crossref: 83] [Cited by in F6Publishing: 36] [Article Influence: 83.0] [Reference Citation Analysis]
113 Carbone M, Adusumilli PS, Alexander HR Jr, Baas P, Bardelli F, Bononi A, Bueno R, Felley-Bosco E, Galateau-Salle F, Jablons D, Mansfield AS, Minaai M, de Perrot M, Pesavento P, Rusch V, Severson DT, Taioli E, Tsao A, Woodard G, Yang H, Zauderer MG, Pass HI. Mesothelioma: Scientific clues for prevention, diagnosis, and therapy. CA Cancer J Clin 2019;69:402-29. [PMID: 31283845 DOI: 10.3322/caac.21572] [Cited by in Crossref: 115] [Cited by in F6Publishing: 98] [Article Influence: 57.5] [Reference Citation Analysis]
114 Hu H, Zhu Y, Pu N, Burkhart RA, Burns W, Laheru D, Zheng L, He J, Goggins MG, Yu J. Association of Germline Variants in Human DNA Damage Repair Genes and Response to Adjuvant Chemotherapy in Resected Pancreatic Ductal Adenocarcinoma. J Am Coll Surg 2020;231:527-535.e14. [PMID: 32659497 DOI: 10.1016/j.jamcollsurg.2020.06.019] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
115 Perego P, Robert J. Oxaliplatin in the era of personalized medicine: from mechanistic studies to clinical efficacy. Cancer Chemother Pharmacol 2016;77:5-18. [PMID: 26589793 DOI: 10.1007/s00280-015-2901-x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 5.2] [Reference Citation Analysis]
116 Kleeff J, Korc M, Apte M, La Vecchia C, Johnson CD, Biankin AV, Neale RE, Tempero M, Tuveson DA, Hruban RH, Neoptolemos JP. Pancreatic cancer. Nat Rev Dis Primers. 2016;2:16022. [PMID: 27158978 DOI: 10.1038/nrdp.2016.22] [Cited by in Crossref: 657] [Cited by in F6Publishing: 558] [Article Influence: 131.4] [Reference Citation Analysis]
117 . Stellungnahme zur Nutzenbewertung Olaparib (neues Anwendungsgebiet, Pankreaskarzinom, Erhaltungstherapie). Z Gastroenterol 2021;59:483-8. [PMID: 34224122 DOI: 10.1055/a-1484-8161] [Reference Citation Analysis]
118 Kawalerski RR, Leach SD, Escobar-Hoyos LF. Pancreatic cancer driver mutations are targetable through distant alternative RNA splicing dependencies. Oncotarget 2021;12:525-33. [PMID: 33796221 DOI: 10.18632/oncotarget.27901] [Reference Citation Analysis]
119 Singh RR, O'Reilly EM. New Treatment Strategies for Metastatic Pancreatic Ductal Adenocarcinoma. Drugs 2020;80:647-69. [PMID: 32306207 DOI: 10.1007/s40265-020-01304-0] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 16.0] [Reference Citation Analysis]
120 Fulton AJ, Lamarca A, Nuttall C, McCallum L, Pihlak R, O'Reilly D, Lalloo F, McNamara MG, Hubner RA, Clancy T, Valle JW. Identification of patients with pancreatic adenocarcinoma due to inheritable mutation: Challenges of daily clinical practice. World J Gastrointest Oncol 2019;11:102-16. [PMID: 30788038 DOI: 10.4251/wjgo.v11.i2.102] [Reference Citation Analysis]
121 Rahnamay Farnood P, Danesh Pazhooh R, Asemi Z, Yousefi B. DNA damage response and repair in pancreatic cancer development and therapy. DNA Repair (Amst) 2021;103:103116. [PMID: 33882393 DOI: 10.1016/j.dnarep.2021.103116] [Reference Citation Analysis]
122 Lohse I, Borgida A, Cao P, Cheung M, Pintilie M, Bianco T, Holter S, Ibrahimov E, Kumareswaran R, Bristow RG. BRCA1 and BRCA2 mutations sensitize to chemotherapy in patient-derived pancreatic cancer xenografts. Br J Cancer. 2015;113:425-432. [PMID: 26180923 DOI: 10.1038/ bjc.2015.220] [Reference Citation Analysis]
123 Alkassis S, Yazdanpanah O, Philip PA. BRCA mutations in pancreatic cancer and progress in their targeting. Expert Opin Ther Targets 2021;25:547-57. [PMID: 34289788 DOI: 10.1080/14728222.2021.1957462] [Reference Citation Analysis]
124 Gupta N, Yelamanchi R. Pancreatic adenocarcinoma: A review of recent paradigms and advances in epidemiology, clinical diagnosis and management. World J Gastroenterol 2021;27:3158-81. [PMID: 34163104 DOI: 10.3748/wjg.v27.i23.3158] [Reference Citation Analysis]
125 Kimura R, Ohtsuka T, Kubo M, Kajihara A, Fujii A, Watanabe Y, Mori Y, Ikenaga N, Nakata K, Shindo K, Ohuchida K, Nakamura M. FoundationOne® CDx gene profiling in Japanese pancreatic ductal adenocarcinoma patients: a single-institution experience. Surg Today 2021;51:619-26. [PMID: 32885350 DOI: 10.1007/s00595-020-02123-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
126 Fogelman D, Sugar EA, Oliver G, Shah N, Klein A, Alewine C, Wang H, Javle M, Shroff R, Wolff RA. Family history as a marker of platinum sensitivity in pancreatic adenocarcinoma. Cancer Chemother Pharmacol. 2015;76:489-498. [PMID: 26126726 DOI: 10.1007/s00280-015-2788-6] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 6.0] [Reference Citation Analysis]
127 Ahn DH, Ramanathan RK, Bekaii-Saab T. Emerging Therapies and Future Directions in Targeting the Tumor Stroma and Immune System in the Treatment of Pancreatic Adenocarcinoma. Cancers (Basel) 2018;10:E193. [PMID: 29891787 DOI: 10.3390/cancers10060193] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
128 Parikh AR, He Y, Hong TS, Corcoran RB, Clark JW, Ryan DP, Zou L, Ting DT, Catenacci DV, Chao J, Fakih M, Klempner SJ, Ross JS, Frampton GM, Miller VA, Ali SM, Schrock AB. Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy. Oncologist 2019;24:1340-7. [PMID: 31040255 DOI: 10.1634/theoncologist.2019-0034] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 14.5] [Reference Citation Analysis]
129 Jain A, Bhardwaj V. Therapeutic resistance in pancreatic ductal adenocarcinoma: Current challenges and future opportunities. WJG 2021;27:6527-50. [DOI: 10.3748/wjg.v27.i39.6527] [Reference Citation Analysis]
130 Mie T, Sasaki T, Takeda T, Fukuda K, Furukawa T, Yamada Y, Kasuga A, Matsuyama M, Ozaka M, Sasahira N. Comparison of Treatment Outcomes Between Gemcitabine With Nab-Paclitaxel and Modified FOLFIRINOX for First-Line Chemotherapy in Metastatic and Recurrent Pancreatic Cancer: Propensity Score Matching. Pancreas 2021;50:595-601. [PMID: 33939674 DOI: 10.1097/MPA.0000000000001801] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
131 Matsubayashi H, Kiyozumi Y, Ishiwatari H, Uesaka K, Kikuyama M, Ono H. Surveillance of Individuals with a Family History of Pancreatic Cancer and Inherited Cancer Syndromes: A Strategy for Detecting Early Pancreatic Cancers. Diagnostics (Basel) 2019;9:E169. [PMID: 31683730 DOI: 10.3390/diagnostics9040169] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
132 Lowery MA, Kelsen DP, Capanu M, Smith SC, Lee JW, Stadler ZK, Moore MJ, Kindler HL, Golan T, Segal A, Maynard H, Hollywood E, Moynahan M, Salo-Mullen EE, Do RKG, Chen AP, Yu KH, Tang LH, O'Reilly EM. Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma. Eur J Cancer 2018;89:19-26. [PMID: 29223478 DOI: 10.1016/j.ejca.2017.11.004] [Cited by in Crossref: 74] [Cited by in F6Publishing: 66] [Article Influence: 18.5] [Reference Citation Analysis]
133 Yu S, Agarwal P, Mamtani R, Symecko H, Spielman K, O’hara M, O’dwyer PJ, Schneider C, Teitelbaum U, Nathanson KL, Domchek SM, Reiss KA. Retrospective Survival Analysis of Patients With Resected Pancreatic Ductal Adenocarcinoma and a Germline BRCA or PALB2 Mutation. JCO Precision Oncology 2019. [DOI: 10.1200/po.18.00271] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
134 Rochefort P, Lardy-Cleaud A, Sarabi M, Desseigne F, Cattey-Javouhey A, de la Fouchardière C. Long-Term Survivors in Metastatic Pancreatic Ductal Adenocarcinoma: A Retrospective and Matched Pair Analysis. Oncologist 2019;24:1543-8. [PMID: 31164454 DOI: 10.1634/theoncologist.2018-0786] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
135 Baraniskin A, Van Laethem J, Wyrwicz L, Guller U, Wasan HS, Matysiak-budnik T, Gruenberger T, Ducreux M, Carneiro F, Van Cutsem E, Seufferlein T, Schmiegel W. Clinical relevance of molecular diagnostics in gastrointestinal (GI) cancer: European Society of Digestive Oncology (ESDO) expert discussion and recommendations from the 17th European Society for Medical Oncology (ESMO)/World Congress on Gastrointestinal Cancer, Barcelona. European Journal of Cancer 2017;86:305-17. [DOI: 10.1016/j.ejca.2017.09.021] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
136 Franck C, Canbay A, Malfertheiner P, Venerito M. Maintenance Therapy with FOLFIRI after FOLFIRINOX for Advanced Pancreatic Ductal Adenocarcinoma: A Retrospective Single-Center Analysis. J Oncol 2019;2019:5832309. [PMID: 31885579 DOI: 10.1155/2019/5832309] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
137 Kryklyva V, Haj Mohammad N, Morsink FHM, Ligtenberg MJL, Offerhaus GJA, Nagtegaal ID, de Leng WWJ, Brosens LAA. Pancreatic acinar cell carcinoma is associated with BRCA2 germline mutations: a case report and literature review. Cancer Biol Ther 2019;20:949-55. [PMID: 31002019 DOI: 10.1080/15384047.2019.1595274] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
138 Guler I, Askan G, Klostergaard J, Sahin IH. Precision medicine for metastatic colorectal cancer: an evolving era. Expert Rev Gastroenterol Hepatol. 2019;13:919-931. [PMID: 31475851 DOI: 10.1080/17474124.2019.1663174] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 7.5] [Reference Citation Analysis]
139 Kaczor-Urbanowicz KE, Cheng J, King JC, Sedarat A, Pandol SJ, Farrell JJ, Wong DTW, Kim Y. Reviews on Current Liquid Biopsy for Detection and Management of Pancreatic Cancers. Pancreas 2020;49:1141-52. [PMID: 33003085 DOI: 10.1097/MPA.0000000000001662] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
140 Roch AM, Schneider J, Carr RA, Lancaster WP, House MG, Zyromski NJ, Nakeeb A, Schmidt CM, Ceppa EP. Are BRCA1 and BRCA2 gene mutation patients underscreened for pancreatic adenocarcinoma? J Surg Oncol. 2019;119:777-783. [PMID: 30636051 DOI: 10.1002/jso.25376] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
141 Sun P, Li Y, Chao X, Li J, Luo R, Li M, He J. Clinical characteristics and prognostic implications of BRCA-associated tumors in males: a pan-tumor survey. BMC Cancer. 2020;20:994. [PMID: 33054725 DOI: 10.1186/s12885-020-07481-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
142 Rapposelli IG, Zampiga V, Cangini I, Arcangeli V, Ravegnani M, Valgiusti M, Pini S, Tamberi S, Bartolini G, Passardi A, Martinelli G, Calistri D, Frassineti GL, Falcini F, Danesi R. Comprehensive analysis of DNA damage repair genes reveals pathogenic variants beyond BRCA and suggests the need for extensive genetic testing in pancreatic cancer. BMC Cancer 2021;21:611. [PMID: 34034685 DOI: 10.1186/s12885-021-08368-5] [Reference Citation Analysis]
143 Chi J, Chung SY, Parakrama R, Fayyaz F, Jose J, Saif MW. The role of PARP inhibitors in BRCA mutated pancreatic cancer. Therap Adv Gastroenterol 2021;14:17562848211014818. [PMID: 34025781 DOI: 10.1177/17562848211014818] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
144 Chen H, Yang G, Xiao J, Zheng L, You L, Zhang T. Neoantigen-based immunotherapy in pancreatic ductal adenocarcinoma (PDAC). Cancer Lett 2020;490:12-9. [PMID: 32590021 DOI: 10.1016/j.canlet.2020.06.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
145 Zemanek T, Melichar B, Lovecek M, Soucek P, Mohelnikova-Duchonova B. Biomarkers and pathways of chemoresistance and chemosensitivity for personalized treatment of pancreatic adenocarcinoma. Pharmacogenomics 2019;20:113-27. [PMID: 30539680 DOI: 10.2217/pgs-2018-0073] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
146 Margonis GA, Amini N, Andreatos N, Sasaki K, McVey J, Mirza MB, Warner S, Buettner S, Barbon C, Wang J, Pulvirenti A, Angelou A, Kamphues C, Antoniou E, Pikoulis E, Pawlik TM, Kaczirek K, Poultsides G, Wagner D, Endo I, Imai K, Aucejo F, Kreis ME, Wolfgang CL, Weiss MJ. KRAS mutational status impacts pathologic response to pre-hepatectomy chemotherapy: a study from the International Genetic Consortium for Liver Metastases. HPB (Oxford) 2019;21:1527-34. [PMID: 30979646 DOI: 10.1016/j.hpb.2019.03.368] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
147 Knudsen ES, O'Reilly EM, Brody JR, Witkiewicz AK. Genetic Diversity of Pancreatic Ductal Adenocarcinoma and Opportunities for Precision Medicine. Gastroenterology. 2016;150:48-63. [PMID: 26385075 DOI: 10.1053/j.gastro.2015.08.056] [Cited by in Crossref: 63] [Cited by in F6Publishing: 61] [Article Influence: 10.5] [Reference Citation Analysis]
148 Roth MT, Cardin DB, Berlin JD. Recent advances in the treatment of pancreatic cancer. F1000Res. 2020;9. [PMID: 32148767 DOI: 10.12688/f1000research.21981.1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 9.0] [Reference Citation Analysis]
149 Borecka M, Zemankova P, Vocka M, Soucek P, Soukupova J, Kleiblova P, Sevcik J, Kleibl Z, Janatova M. Mutation analysis of the PALB2 gene in unselected pancreatic cancer patients in the Czech Republic. Cancer Genetics 2016;209:199-204. [DOI: 10.1016/j.cancergen.2016.03.003] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 3.2] [Reference Citation Analysis]
150 Orsi G, Di Marco M, Cavaliere A, Niger M, Bozzarelli S, Giordano G, Noventa S, Rapposelli IG, Garajova I, Tortora G, Rodriquenz MG, Bittoni A, Penzo E, De Lorenzo S, Peretti U, Paratore C, Bernardini I, Mosconi S, Spallanzani A, Macchini M, Tamburini E, Bencardino K, Giommoni E, Scartozzi M, Forti L, Valente MM, Militello AM, Cascinu S, Milella M, Reni M. Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic variants (gBRCA1-2pv): a multicenter survey. ESMO Open 2021;6:100238. [PMID: 34392104 DOI: 10.1016/j.esmoop.2021.100238] [Reference Citation Analysis]
151 Hayashi H, Higashi T, Miyata T, Yamashita YI, Baba H. Recent advances in precision medicine for pancreatic ductal adenocarcinoma. Ann Gastroenterol Surg 2021;5:457-66. [PMID: 34337294 DOI: 10.1002/ags3.12436] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
152 Golan T, Kindler HL, Park JO, Reni M, Macarulla T, Hammel P, Van Cutsem E, Arnold D, Hochhauser D, McGuinness D, Locker GY, Goranova T, Schatz P, Liu YZ, Hall MJ. Geographic and Ethnic Heterogeneity of Germline BRCA1 or BRCA2 Mutation Prevalence Among Patients With Metastatic Pancreatic Cancer Screened for Entry Into the POLO Trial. J Clin Oncol 2020;38:1442-54. [PMID: 32073954 DOI: 10.1200/JCO.19.01890] [Cited by in Crossref: 17] [Cited by in F6Publishing: 8] [Article Influence: 17.0] [Reference Citation Analysis]
153 Yang G, Yin J, Ou K, Du Q, Ren W, Jin Y, Peng L, Yang L. Undifferentiated carcinoma with osteoclast-like giant cells of the pancreas harboring KRAS and BRCA mutations: case report and whole exome sequencing analysis. BMC Gastroenterol 2020;20:202. [PMID: 32590950 DOI: 10.1186/s12876-020-01351-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
154 Pishvaian MJ, Blais EM, Brody JR, Rahib L, Lyons E, De Arbeloa P, Hendifar A, Mikhail S, Chung V, Sohal DP, Leslie S, Mason K, Tibbets L, Madhavan S, Matrisian LM, Petricoin E. Outcomes in Patients With Pancreatic Adenocarcinoma With Genetic Mutations in DNA Damage Response Pathways: Results From the Know Your Tumor Program. JCO Precision Oncology 2019. [DOI: 10.1200/po.19.00115] [Cited by in Crossref: 10] [Cited by in F6Publishing: 1] [Article Influence: 5.0] [Reference Citation Analysis]
155 Parkin A, Man J, Chou A, Nagrial AM, Samra J, Gill AJ, Timpson P, Pajic M. The Evolving Understanding of the Molecular and Therapeutic Landscape of Pancreatic Ductal Adenocarcinoma. Diseases 2018;6:E103. [PMID: 30428574 DOI: 10.3390/diseases6040103] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
156 Matsubayashi H, Takaori K, Morizane C, Kiyozumi Y. Familial Pancreatic Cancer and Surveillance of High-Risk Individuals. Gut Liver 2019;13:498-505. [PMID: 30917631 DOI: 10.5009/gnl18449] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
157 Blair AB, Groot VP, Gemenetzis G, Wei J, Cameron JL, Weiss MJ, Goggins M, Wolfgang CL, Yu J, He J. BRCA1/BRCA2 Germline Mutation Carriers and Sporadic Pancreatic Ductal Adenocarcinoma. J Am Coll Surg 2018;226:630-637.e1. [PMID: 29309945 DOI: 10.1016/j.jamcollsurg.2017.12.021] [Cited by in Crossref: 32] [Cited by in F6Publishing: 24] [Article Influence: 10.7] [Reference Citation Analysis]
158 Golan T, Atias D, Stossel C, Raitses-Gurevich M. Patient-derived xenograft models of BRCA-associated pancreatic cancers. Adv Drug Deliv Rev 2021;171:257-65. [PMID: 33617901 DOI: 10.1016/j.addr.2021.02.010] [Reference Citation Analysis]
159 Llach J, Carballal S, Moreira L. Familial Pancreatic Cancer: Current Perspectives. Cancer Manag Res 2020;12:743-58. [PMID: 32099470 DOI: 10.2147/CMAR.S172421] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 10.0] [Reference Citation Analysis]
160 Okuwaki K, Masutani H, Imaizumi H, Yoshida T, Kida M, Iwai T, Yamauchi H, Tadehara M, Adachi K, Watanabe M, Kurosu T, Koizumi W. Analysis of BRCAness with multiplex ligation-dependent probe amplification using formalin-fixed and paraffin-embedded pancreatic ductal adenocarcinoma tissue obtained via endoscopic ultrasound-guided fine-needle aspiration biopsy. Pancreatology 2019;19:419-23. [PMID: 30819577 DOI: 10.1016/j.pan.2019.02.010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
161 Hasan S, Jacob R, Manne U, Paluri R. Advances in pancreatic cancer biomarkers. Oncol Rev 2019;13:410. [PMID: 31044028 DOI: 10.4081/oncol.2019.410] [Cited by in Crossref: 39] [Cited by in F6Publishing: 30] [Article Influence: 19.5] [Reference Citation Analysis]
162 Mehta A, Hwang WL, Weekes C. The present and future of systemic and microenvironment-targeted therapy for pancreatic adenocarcinoma. Ann Pancreat Cancer 2020;3:3. [PMID: 33294843 DOI: 10.21037/apc-2020-pda-05] [Reference Citation Analysis]
163 Halder R, Shroff RT. What is the role of PARP inhibitors in pancreatic cancer? Expert Rev Anticancer Ther 2020;20:913-8. [PMID: 32865047 DOI: 10.1080/14737140.2020.1816174] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
164 Cetin R, Quandt E, Kaulich M. Functional Genomics Approaches to Elucidate Vulnerabilities of Intrinsic and Acquired Chemotherapy Resistance. Cells 2021;10:260. [PMID: 33525637 DOI: 10.3390/cells10020260] [Reference Citation Analysis]
165 Zeng Y, Rucki AA, Che X, Zheng L. Shifting paradigm of developing biologics for the treatment of pancreatic adenocarcinoma. J Gastrointest Oncol 2017;8:441-8. [PMID: 28736631 DOI: 10.21037/jgo.2016.10.02] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
166 Lowery MA, O'reilly EM. Novel Therapeutics for Pancreatic Adenocarcinoma. Hematology/Oncology Clinics of North America 2015;29:777-87. [DOI: 10.1016/j.hoc.2015.04.006] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
167 Armstrong SA, Schultz CW, Azimi-Sadjadi A, Brody JR, Pishvaian MJ. ATM Dysfunction in Pancreatic Adenocarcinoma and Associated Therapeutic Implications. Mol Cancer Ther 2019;18:1899-908. [PMID: 31676541 DOI: 10.1158/1535-7163.MCT-19-0208] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 17.0] [Reference Citation Analysis]
168 Connor AA, Gallinger S. Next generation sequencing of pancreatic ductal adenocarcinoma: right or wrong? Expert Rev Gastroenterol Hepatol 2017;11:683-94. [PMID: 28460572 DOI: 10.1080/17474124.2017.1324296] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
169 Lambert A, Conroy T, Ducreux M. Future directions in drug development in pancreatic cancer. Semin Oncol 2021:S0093-7754(21)00007-5. [PMID: 33674067 DOI: 10.1053/j.seminoncol.2021.02.002] [Reference Citation Analysis]
170 Verdaguer H, Saurí T, Macarulla T. Predictive and prognostic biomarkers in personalized gastrointestinal cancer treatment. J Gastrointest Oncol 2017;8:405-17. [PMID: 28736628 DOI: 10.21037/jgo.2016.11.15] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
171 Matsubayashi H, Takaori K, Morizane C, Maguchi H, Mizuma M, Takahashi H, Wada K, Hosoi H, Yachida S, Suzuki M, Usui R, Furukawa T, Furuse J, Sato T, Ueno M, Kiyozumi Y, Hijioka S, Mizuno N, Terashima T, Mizumoto M, Kodama Y, Torishima M, Kawaguchi T, Ashida R, Kitano M, Hanada K, Furukawa M, Kawabe K, Majima Y, Shimosegawa T. Familial pancreatic cancer: Concept, management and issues. World J Gastroenterol 2017;23:935-48. [PMID: 28246467 DOI: 10.3748/wjg.v23.i6.935] [Cited by in CrossRef: 45] [Cited by in F6Publishing: 36] [Article Influence: 11.3] [Reference Citation Analysis]
172 Chang Q, Ornatsky OI, Siddiqui I, Straus R, Baranov VI, Hedley DW. Biodistribution of cisplatin revealed by imaging mass cytometry identifies extensive collagen binding in tumor and normal tissues. Sci Rep 2016;6:36641. [PMID: 27812005 DOI: 10.1038/srep36641] [Cited by in Crossref: 47] [Cited by in F6Publishing: 40] [Article Influence: 9.4] [Reference Citation Analysis]
173 Beatty GL, Werba G, Lyssiotis CA, Simeone DM. The biological underpinnings of therapeutic resistance in pancreatic cancer. Genes Dev 2021;35:940-62. [PMID: 34117095 DOI: 10.1101/gad.348523.121] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]